Background Despite increasing worldwide use of anti-vascular endothelial growth factor
agents for treatment of retinopathy of prematurity (ROP), there are few data on their ocular …

Introduction Laser photocoagulation is the current gold standard treatment for proliferative
retinopathy of prematurity (ROP). However, it permanently reduces the visual field and might …

Background Retinopathy of prematurity is a leading cause of childhood blindness
worldwide. Peripheral retinal ablation with conventional (confluent) laser therapy is …

Retinopathy of prematurity (ROP) is a vasoproliferative disease of developing retinal vessels
that affects premature infants and can lead to severe and irreversible visual loss if left …

The authors review published clinical case reports, case series, and clinical trials evaluating
the use of anti-vascular endothelial growth factor (VEGF) medications for the primary or …

Background: To evaluate the therapeutic effect of a single intravitreal injection of
bevacizumab for treatment of threshold retinopathy in retinopathy of prematurity (ROP) …

Purpose To compare long-term refractive outcomes associated with intravitreal anti-vascular
endothelial growth factor (VEGF) versus laser photocoagulation treatment for retinopathy of …

Purpose To evaluate, in a combined treatment strategy for treatment-warranted retinopathy
of prematurity (ROP), which of the two is a better treatment sequence, peripheral laser …

This article is aimed to review and summarize the indications, outcomes and safety profiles
regarding the use of intravitreal bevacizumab in patients with retinopathy of prematurity …

Purpose The aim of the study was to evaluate the role of anti-VEGF therapy as an adjunct to
laser ablation therapy in severe aggressive posterior retinopaty of prematurity (AP-ROP) …